RESUMO
BACKGROUND: The increasing multidrug resistance among gram-negative uropathogens necessitates new treatments for serious infections. Plazomicin is an aminoglycoside with bactericidal activity against multidrug-resistant (including carbapenem-resistant) Enterobacteriaceae. METHODS: We randomly assigned 609 patients with complicated urinary tract infections (UTIs), including acute pyelonephritis, in a 1:1 ratio to receive intravenous plazomicin (15 mg per kilogram of body weight once daily) or meropenem (1 g every 8 hours), with optional oral step-down therapy after at least 4 days of intravenous therapy, for a total of 7 to 10 days of therapy. The primary objective was to show the noninferiority of plazomicin to meropenem in the treatment of complicated UTIs, including acute pyelonephritis, with a noninferiority margin of 15 percentage points. The primary end points were composite cure (clinical cure and microbiologic eradication) at day 5 and at the test-of-cure visit (15 to 19 days after initiation of therapy) in the microbiologic modified intention-to-treat population. RESULTS: Plazomicin was noninferior to meropenem with respect to the primary efficacy end points. At day 5, composite cure was observed in 88.0% of the patients (168 of 191 patients) in the plazomicin group and in 91.4% (180 of 197 patients) in the meropenem group (difference, -3.4 percentage points; 95% confidence interval [CI], -10.0 to 3.1). At the test-of-cure visit, composite cure was observed in 81.7% (156 of 191 patients) and 70.1% (138 of 197 patients), respectively (difference, 11.6 percentage points; 95% CI, 2.7 to 20.3). At the test-of-cure visit, a higher percentage of patients in the plazomicin group than in the meropenem group were found to have microbiologic eradication, including eradication of Enterobacteriaceae that were not susceptible to aminoglycosides (78.8% vs. 68.6%) and Enterobacteriaceae that produce extended-spectrum ß-lactamases (82.4% vs. 75.0%). At late follow-up (24 to 32 days after initiation of therapy), fewer patients in the plazomicin group than in the meropenem group had microbiologic recurrence (3.7% vs. 8.1%) or clinical relapse (1.6% vs. 7.1%). Increases in serum creatinine levels of 0.5 mg or more per deciliter (≥40 µmol per liter) above baseline occurred in 7.0% of patients in the plazomicin group and in 4.0% in the meropenem group. CONCLUSIONS: Once-daily plazomicin was noninferior to meropenem for the treatment of complicated UTIs and acute pyelonephritis caused by Enterobacteriaceae, including multidrug-resistant strains. (Funded by Achaogen and the Biomedical Advanced Research and Development Authority; EPIC ClinicalTrials.gov number, NCT02486627.).
Assuntos
Antibacterianos/administração & dosagem , Infecções por Enterobacteriaceae/tratamento farmacológico , Meropeném/administração & dosagem , Sisomicina/análogos & derivados , Infecções Urinárias/tratamento farmacológico , Administração Intravenosa , Administração Oral , Adulto , Idoso , Antibacterianos/efeitos adversos , Esquema de Medicação , Farmacorresistência Bacteriana Múltipla , Enterobacteriaceae/efeitos dos fármacos , Feminino , Humanos , Masculino , Meropeném/efeitos adversos , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Gravidade do Paciente , Sisomicina/administração & dosagem , Sisomicina/efeitos adversos , Infecções Urinárias/microbiologiaRESUMO
BACKGROUND: Killing of bacterial pathogens by granulocytes is a saturable process, as previously demonstrated. There is virtually no quantitative information about how granulocytes interact with antimicrobial chemotherapy to kill bacterial cells. METHODS: We performed a dose-ranging study with the aminoglycoside plazomicin against Pseudomonas aeruginosa ATCC27853 in a granulocyte-replete murine pneumonia model. Plazomicin was administered in a humanized fashion (ie, administration of decrementing doses 5 times over 24 hours, mimicking a human daily administration profile). Pharmacokinetic profiling was performed in plasma and epithelial lining fluid. All samples were simultaneously analyzed with a population model. Mouse cohorts were treated for 24 hours; other cohorts treated with the same therapy were observed for another 24 hours after therapy cessation, allowing delineation of the therapeutic effect necessary to reduce the bacterial burden to a level below the half-saturation point. RESULTS: The mean bacterial burden (±SD) at which granulocyte-mediated kill was half saturable was 2.45 × 10(6) ± 6.84 × 10(5) colony-forming units of bacteria per gram of tissue (CFU/g). Higher levels of plazomicin exposure reduced the bacterial burden to <5 log10 CFU/g, allowing granulocytes to kill an additional 1.0-1.5 log CFU/g over the subsequent 24 hours. CONCLUSIONS: For patients with large bacterial burdens (eg, individuals with ventilator-requiring hospital-acquired pneumonia), it is imperative to kill ≥2 log10 CFU/g early after treatment initiation, to allow the granulocytes to contribute optimally to bacterial clearance.
Assuntos
Granulócitos/fisiologia , Pneumonia Bacteriana/microbiologia , Infecções por Pseudomonas/microbiologia , Pseudomonas aeruginosa/fisiologia , Sisomicina/análogos & derivados , Animais , Antibacterianos/administração & dosagem , Antibacterianos/farmacocinética , Antibacterianos/uso terapêutico , Relação Dose-Resposta a Droga , Farmacorresistência Bacteriana , Feminino , Camundongos , Testes de Sensibilidade Microbiana , Pneumonia Bacteriana/tratamento farmacológico , Pneumonia Bacteriana/imunologia , Infecções por Pseudomonas/tratamento farmacológico , Infecções por Pseudomonas/imunologia , Sisomicina/administração & dosagem , Sisomicina/farmacocinética , Sisomicina/uso terapêuticoRESUMO
ACHN-490 is an aminoglycoside with activity against multidrug-resistant pathogens, including those resistant to currently used aminoglycosides. Two randomized, double-blind, placebo-controlled clinical studies investigated the pharmacokinetics (PK), safety, and tolerability of ACHN-490 injection in healthy subjects. Study 1 used a parallel-group design with escalating single (SD) and multiple doses (MD). Study 2 explored a longer duration of the highest dose tolerated in the first study. Subjects were randomly assigned to receive either ACHN-490 injection or a placebo administered by a 10-min intravenous infusion. Study 1 enrolled 39 subjects (30 active and 9 placebo) and consisted of a single dose of 1 mg/kg body weight followed by ascending SD and MD cohorts of 4, 7, 11, and 15 mg/kg for 10, 10, 5, and 3 days, respectively. Study 2 enrolled 8 subjects (6 active and 2 placebo) who received 15 mg/kg for 5 days. Safety was assessed from adverse event (AE) reporting, standard clinical laboratory procedures, and testing for renal, cochlear, and vestibular function. ACHN-490 exhibited linear and dose-proportional PK, with agreement between the studies for PK parameters assessed. The 15-mg/kg dose did not accumulate with repeated dosing over 5 days. Mean steady-state (±standard deviation) area under the concentration-time curve from 0 to 24 h (AUC(0-24)), maximum concentration of drug in serum (C(max)), half-life (t(1/2)), clearance, and volume of distribution at steady state (V(ss)) for the 15-mg/kg, day 5 dose were 239 ± 45 h·mg/liter, 113 ± 17 mg/liter, 3 ± 0.3 h, 1.1 ± 0.1 ml/min/kg, and 0.24 ± 0.04 liters/kg, respectively. AEs were mild to moderate and rapidly resolved. No evidence of nephrotoxicity or ototoxicity was observed.
Assuntos
Antibacterianos/efeitos adversos , Antibacterianos/farmacocinética , Sisomicina/análogos & derivados , Adolescente , Adulto , Antibacterianos/administração & dosagem , Área Sob a Curva , Relação Dose-Resposta a Droga , Método Duplo-Cego , Esquema de Medicação , Feminino , Meia-Vida , Humanos , Infusões Intravenosas , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Sisomicina/administração & dosagem , Sisomicina/efeitos adversos , Sisomicina/farmacocinética , Resultado do Tratamento , Adulto JovemRESUMO
Antimicrobial resistance is a growing threat to public health and an increasingly common problem for acute care physicians to confront. Several novel antibiotics have been approved in the past decade to combat these infections; however, physicians may be unfamiliar with how to appropriately utilize them. The purpose of this review is to evaluate novel antibiotics active against resistant gram-negative bacteria and highlight clinical information regarding their use in the acute care setting. This review focuses on novel antibiotics useful in the treatment of infections caused by resistant gram-negative organisms that may be seen in the acute care setting. These novel antibiotics include ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilistatin/relebactam, cefiderocol, plazomicin, eravacycline, and omadacycline. Acute care physicians should be familiar with these novel antibiotics so they can utilize them appropriately.
Assuntos
Antibacterianos , Desenho de Fármacos , Resistência a Múltiplos Medicamentos/efeitos dos fármacos , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Compostos Azabicíclicos/administração & dosagem , Compostos Azabicíclicos/farmacologia , Ácidos Borônicos/administração & dosagem , Ácidos Borônicos/farmacologia , Ceftazidima/administração & dosagem , Ceftazidima/farmacologia , Cefalosporinas/administração & dosagem , Cefalosporinas/farmacologia , Combinação Imipenem e Cilastatina/administração & dosagem , Combinação Imipenem e Cilastatina/farmacologia , Combinação de Medicamentos , Bactérias Gram-Negativas/efeitos dos fármacos , Compostos Heterocíclicos com 1 Anel/administração & dosagem , Compostos Heterocíclicos com 1 Anel/farmacologia , Humanos , Meropeném/administração & dosagem , Meropeném/farmacologia , Sisomicina/administração & dosagem , Sisomicina/análogos & derivados , Sisomicina/farmacologia , Tazobactam/administração & dosagem , Tazobactam/farmacologia , Tetraciclinas/administração & dosagem , Tetraciclinas/farmacologia , CefiderocolRESUMO
Sensory hair cells are prone to apoptosis caused by various drugs including aminoglycoside antibiotics. In mammals, this vulnerability results in permanent hearing loss because lost hair cells are not regenerated. Conversely, hair cells regenerate in birds, making the avian inner ear an exquisite model for studying ototoxicity and regeneration. Here, we use single-cell RNA sequencing and trajectory analysis on control and dying hair cells after aminoglycoside treatment. Interestingly, the two major subtypes of avian cochlear hair cells, tall and short hair cells, respond differently. Dying short hair cells show a noticeable transient upregulation of many more genes than tall hair cells. The most prominent gene group identified is associated with potassium ion conductances, suggesting distinct physiological differences. Moreover, the dynamic characterization of >15,000 genes expressed in tall and short avian hair cells during their apoptotic demise comprises a resource for further investigations toward mammalian hair cell protection and hair cell regeneration.
Assuntos
Galinhas/genética , Células Ciliadas Auditivas/patologia , Transcriptoma/genética , Aminoglicosídeos/farmacologia , Animais , Morte Celular/efeitos dos fármacos , Morte Celular/genética , Perfilação da Expressão Gênica , Regulação da Expressão Gênica/efeitos dos fármacos , Células Ciliadas Auditivas/efeitos dos fármacos , Canais Semicirculares/efeitos dos fármacos , Canais Semicirculares/metabolismo , Sisomicina/administração & dosagem , Sisomicina/farmacologia , Fatores de Tempo , Transcriptoma/efeitos dos fármacosRESUMO
INTRODUCTION: Antimicrobial resistance continues to be a major public health concern due to the emergence and spread of multi-drug resistant (MDR) organisms, including extended spectrum ß-lactamase (ESBL) and carbapenemase producing Enterobacterales. Plazomicin is a novel aminoglycoside that demonstrates activity against MDR gram-negatives, including those producing ESBLs and most carbapenemases, and retains activity against aminoglycoside modifying enzymes as a result of structural modifications. The information discussed is meant to assist in identifying plazomicin's place in therapy and to expand the clinician's armamentarium. AREAS COVERED: Herein, we review the pharmacology, microbiology, clinical efficacy, and safety of plazomicin. To gather relevant information, a literature search was performed using PubMed, Ovid, and Google Scholar electronic databases. Search terms used include plazomicin, ACHN-490, extended spectrum ß-lactamase, ESBL, CRE, aminoglycoside modifying enzymes, and AME. Additional information was obtained from FDA review documents and research abstracts presented at international conferences. EXPERT OPINION: Plazomicin is a promising carbapenem or ß-lactam/ß-lactamase inhibitor-sparing alternative for the treatment of complicated urinary tract infections caused by MDR Enterobacterales. Although robust data for bloodstream infections and bacterial pneumonias are lacking, plazomicin may be considered in individual clinical scenarios if combination therapy is warranted provided supportive microbiological data and therapeutic drug monitoring are available.
Assuntos
Infecções por Enterobacteriaceae/tratamento farmacológico , Sisomicina/análogos & derivados , Infecções Urinárias/tratamento farmacológico , Animais , Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Antibacterianos/farmacologia , Farmacorresistência Bacteriana Múltipla , Enterobacteriaceae/efeitos dos fármacos , Infecções por Enterobacteriaceae/microbiologia , Humanos , Sisomicina/administração & dosagem , Sisomicina/efeitos adversos , Sisomicina/farmacologia , Infecções Urinárias/microbiologiaRESUMO
Plazomicin is an aminoglycoside that was engineered to overcome aminoglycoside-modifying enzymes, which are the most common aminoglycoside resistance mechanism in Enterobacteriaceae. Because plazomicin is predominantly eliminated via renal pathways, an in vitro study was conducted to determine whether plazomicin inhibits the organic cation transporter 2 (OCT2) and the multidrug and toxin extrusion (MATE1 and MATE2-K) transporters, using metformin as a probe substrate. Plazomicin inhibited OCT2, MATE1, and MATE2-K transporters with half-maximal inhibition of the transporter values of 5120, 1300, and 338 µg/mL, respectively. To determine whether this in vitro inhibition translates in vivo, an open-label, randomized, 2-period, 2-treatment crossover study (NCT03270553) was carried out in healthy subjects (N = 16), who received a single oral dose of metformin 850 mg alone and in combination with a single intravenous infusion of plazomicin 15 mg/kg. Geometric least-squares mean ratios of the test treatment (combination) vs the reference treatment (metformin alone) and 90% confidence intervals were within the equivalence interval of 80% to 125% (peak plasma concentration, 104.5 [95.1-114.9]; area under the plasma concentration-time curve from time zero to time of last quantifiable concentration, 103.7 [93.5-115.0]; area under the plasma concentration-time curve from time zero to infinity, 104.0 [94.2-114.8]). The results demonstrate that there is no clinically significant drug-drug interaction resulting from coadministration of single doses of intravenous plazomicin 15 mg/kg and oral metformin 850 mg in healthy subjects. Coadministration of plazomicin and metformin was well tolerated in healthy subjects.
Assuntos
Metformina/farmacocinética , Proteínas de Transporte de Cátions Orgânicos/metabolismo , Transportador 2 de Cátion Orgânico/metabolismo , Sisomicina/análogos & derivados , Administração Intravenosa , Administração Oral , Adulto , Área Sob a Curva , Estudos Cross-Over , Interações Medicamentosas , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Células HEK293 , Voluntários Saudáveis , Humanos , Masculino , Metformina/administração & dosagem , Sisomicina/administração & dosagem , Sisomicina/farmacologia , Adulto JovemRESUMO
PURPOSE: In the Phase III Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CARE), plazomicin was studied for the treatment of critically ill patients with infections caused by carbapenem-resistant Enterobacterales. Initial plazomicin dosing was guided by creatinine clearance (CrCl) and subsequent doses adjusted by therapeutic drug monitoring to achieve AUC0-24 exposures within a target range (210-315 mgâh/L). We applied the Hartford nomogram to evaluate whether this clinical tool could reduce plazomicin troughs levels and increase the proportion of patients within the target AUC range. METHODS: Thirty-seven patients enrolled in cohorts 1 or 2 of CARE were eligible for analyses. Observed 10-hour concentrations after the initial dose were plotted on the Hartford nomogram to determine an eligible dosing interval group (q24h, q36h or q48h). On the basis of baseline CrCl, a 15- or 10-mg/kg dose was simulated with the nomogram-recommended dosing interval. The proportion of patients in each dosing interval group with a trough ≥3 mg/L (trough threshold associated with serum creatinine increases ≥0.5 mg/dL in product label) was quantified. Simulated interval-normalized AUC0-24 was compared with the target AUC range. FINDINGS: Among the 28 patients with a CrCl ≥60 mL/min, the nomogram recommended every-24-hour dosing in 61% and an extended-interval (q36h or q48h) in 39% of patients. For patients with a CrCl ≥30-59 mL/min (n = 9), the nomogram recommended every-24-hour dosing and an extended-interval in 22% and 78% of patients, respectively. Among both renal function cohorts, exposure simulation with the nomogram significantly reduced the proportion of patients with trough concentrations ≥3 mg/L (CrCl ≥60 mL/min cohort: 91% vs 9%, P < 0.001; CrCl ≥30-59 mL/min cohort, 100% vs 0%, P < 0.001). Relative to the observed mean (SD) AUC0-24 of 309 mgâh/mL (96 mgâh/mL), simulation of extended intervals resulted in a mean interval-normalized AUC0-24 of 210 mgâh/mL (40 mgâh/mL) in all patients eligible for an extended interval, resulting in a similar proportion (49% vs 54%) of patients within the target AUC0-24 range after the first dose. IMPLICATIONS: Application of the Hartford nomogram successfully reduced the likelihood of elevated plazomicin trough concentrations while improving AUC exposures in these patients with carbapenem-resistant Enterobacterales infections.
Assuntos
Antibacterianos/administração & dosagem , Farmacorresistência Bacteriana , Infecções por Enterobacteriaceae/tratamento farmacológico , Sisomicina/análogos & derivados , Idoso , Antibacterianos/sangue , Antibacterianos/farmacocinética , Carbapenêmicos , Simulação por Computador , Creatinina/sangue , Estado Terminal , Esquema de Medicação , Monitoramento de Medicamentos , Feminino , Hospitais , Humanos , Masculino , Pessoa de Meia-Idade , Nomogramas , Sisomicina/administração & dosagem , Sisomicina/sangue , Sisomicina/farmacocinéticaRESUMO
Plazomicin is a novel aminoglycoside antibiotic that binds to the bacterial 30S ribosomal subunit, thus inhibiting protein synthesis in a concentration-dependent manner. Plazomicin displays a broad spectrum of activity against aerobic gram-negative bacteria including extended-spectrum ß-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and organisms with aminoglycoside-modifying enzymes. In a large phase III clinical trial, plazomicin was shown to be noninferior to meropenem in the treatment of complicated urinary tract infections (cUTIs) with respect to the coprimary efficacy end points of the microbiologically modified intent-to-treat composite cure rate at day 5 (plazomicin 88% [168/191 subjects] vs meropenem 91.4% [180/197]) and at the test-of-cure visit (plazomicin 81.7% [156/191] vs meropenem 70.1% [138/197]). In a small phase III clinical trial, plazomicin was shown to be effective in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. It was associated with a lower all-cause mortality or significant disease-related complication rate (23.5% [4/17]) compared with colistin (50% [10/20]). The most common adverse reactions associated with plazomicin are decreased renal function, diarrhea, hypertension, headache, nausea, vomiting, and hypotension. As with other aminoglycosides, plazomicin may cause neuromuscular blockade, ototoxicity, and fetal harm in pregnant women. Due to limited efficacy and safety data, plazomicin is indicated for the treatment of cUTIs in adults with limited or no alternative treatment options, using a dosage regimen of 15 mg/kg intravenously every 24 hours for 4-7 days. Dosage reductions and therapeutic drug monitoring are warranted in patients with moderate or severe renal impairment. Plazomicin is not recommended in patients with severe renal impairment including those receiving renal replacement therapy. With the approval of plazomicin, clinicians now have an additional option for the treatment of adults with cUTIs, particularly those caused by multidrug-resistant gram-negative rods.
Assuntos
Antibacterianos/administração & dosagem , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Sisomicina/análogos & derivados , Adulto , Antibacterianos/efeitos adversos , Relação Dose-Resposta a Droga , Monitoramento de Medicamentos/métodos , Farmacorresistência Bacteriana Múltipla , Bactérias Gram-Negativas/efeitos dos fármacos , Infecções por Bactérias Gram-Negativas/microbiologia , Humanos , Sisomicina/administração & dosagem , Sisomicina/efeitos adversos , Infecções Urinárias/tratamento farmacológico , Infecções Urinárias/microbiologiaRESUMO
Plazomicin is an aminoglycoside with in vitro activity against multidrug-resistant Enterobacteriaceae. A phase 1, randomized, double-blind, crossover study assessed the potential effects of plazomicin on cardiac repolarization (NCT01514929). Fifty-six healthy adults (24 men, 32 women) received a single therapeutic dose of plazomicin (15 mg/kg administered by 30-minute intravenous infusion), a single supratherapeutic dose of plazomicin (20 mg/kg administered by 30-minute intravenous infusion), placebo, or oral moxifloxacin (400 mg). The primary end point was the baseline-adjusted, placebo-corrected QTc interval using the Fridericia formula (ΔΔQTcF). Assay sensitivity was concluded if the lower limit of a 1-sided 95%CI (adjusted for multiplicity using the Hochberg procedure) for moxifloxacin ΔΔQTcF was >5 milliseconds at ≥1 prespecified time points. No QT prolongation effect for plazomicin was concluded if the largest mean effect was <5 milliseconds, and the upper limit of a 2-sided 90%CI for plazomicin ΔΔQTcF was <10 milliseconds at all time points. Assay sensitivity was demonstrated based on moxifloxacin ΔΔQTcF. No QT prolongation effect for plazomicin was concluded because the largest mean ΔΔQTcF for plazomicin was 3.5 milliseconds, and the highest upper limit was 5.6 milliseconds. No clinically relevant changes were observed in electrocardiograms. For the 15- and 20-mg/kg dose levels of plazomicin, mean peak plasma concentration values were 76.0 and 96.6 mg/L, and mean values of the area under the concentration-time curve over 24 hours were 263 and 327 mg·h/L, respectively. Model-derived pharmacokinetic parameters and safety findings were generally consistent with previously reported plazomicin studies. In conclusion, therapeutic and supratherapeutic doses of plazomicin had no clinically significant effect on cardiac repolarization and were generally well tolerated.
Assuntos
Antibacterianos , Síndrome do QT Longo/induzido quimicamente , Sisomicina/análogos & derivados , Adulto , Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Antibacterianos/sangue , Área Sob a Curva , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Eletrocardiografia/efeitos dos fármacos , Feminino , Frequência Cardíaca/efeitos dos fármacos , Humanos , Infusões Intravenosas , Síndrome do QT Longo/sangue , Síndrome do QT Longo/epidemiologia , Masculino , Sisomicina/administração & dosagem , Sisomicina/efeitos adversos , Sisomicina/sangueRESUMO
The kinetic parameters of netilmicin were studied in normal human subjects. In the intravenous study a steady-state was obtained in 4 subjects by the constant infusion of 2 mg/kg of netilmicin during the first hour followed by 0.5 mg/kg/hr for each of three successive hours. Creatinine clearance was greater than the simultaneous serum and renal clearance of netilmicin. In the intramuscular study 6 subjects received a single injection of 1 mg/kg of netilmicin followed by the same dose of gentamicin 1 wk later. A mean peak serum levels of 3.9 microgram/ml was found for both antibiotics, but the mean serum half-life of netilmicin was shorter than that of gentamicin. Doubling the intramuscular dose of netilmicin approximately doubled the peak serum level. In both studies 75% to 90% of the netilmicin was recovered in the urine within the first 24 hr. Netilmicin appears to be primarily excreted by glomerular filtration. The apparent volume of distribution was similar to that reported for other related aminoglycosides. Netilmicin and gentamicin have similar kinetic parameters. There were wide individual differences among normal subjects with both drugs.
Assuntos
Gentamicinas/metabolismo , Sisomicina/metabolismo , Feminino , Gentamicinas/administração & dosagem , Humanos , Infusões Parenterais , Injeções Intramusculares , Cinética , Masculino , Sisomicina/administração & dosagem , Sisomicina/análogos & derivadosRESUMO
The kinetics of netilmicin (N-ethyl-sisomicin), an investigational aminoglycoside, have been determined in man following intravenous and intramuscular administration of a dose of 2 mg/kg. After intravenous injection the serum elimination of the antibiotic obeys two-compartment open model kinetics. Distribution and elimination constants are in the range reported for other aminoglycosides, with the exception of the volume of distribution at the steady-state, which appears to be greater than that of sisomicin and of tobramycin. Urinary excretion data suggest that this antibiotic undergoes some degree of tubular reabsorption and appears to be cleared partially by extrarenal processes. After intramuscular administration, the absorption of netilmicin follows first-order kinetics and its physiologic availability is complete.
Assuntos
Gentamicinas/metabolismo , Sisomicina/metabolismo , Absorção , Adulto , Feminino , Humanos , Injeções Intramusculares , Injeções Intravenosas , Cinética , Masculino , Modelos Biológicos , Sisomicina/administração & dosagem , Sisomicina/análogos & derivadosRESUMO
Sisomicin or a placebo was administered endotracheally to two groups of 18 and 20 unconscious patients, respectively, who had tracheostomies or endotracheal tubes in place and developed a severe gram-negative broncho-pneumonia. In addition, the patients received systemically a combination of sisomicin and carbenicillin. A favorable clinical response was obtained in 14 (77 percent) of the 18 patients who were treated with sisomicin and in nine (45 percent) of the 20 patients who received the placebo (P less than 0.05). Endotracheal therapy with sisomicin was well tolerated and resulted in high levels of sisomicin and in elevated bactericidal activity within the bronchial secretions. Endotracheally administered amino-glycosides might be an important adjunct to systemically administered antibiotics in the management of severe gram-negative bronchopneumonia.
Assuntos
Infecções Bacterianas/tratamento farmacológico , Broncopneumonia/tratamento farmacológico , Carbenicilina/administração & dosagem , Gentamicinas/administração & dosagem , Sisomicina/administração & dosagem , Brônquios/metabolismo , Broncopneumonia/microbiologia , Carbenicilina/metabolismo , Carbenicilina/uso terapêutico , Ensaios Clínicos como Assunto , Método Duplo-Cego , Avaliação de Medicamentos , Quimioterapia Combinada , Infecções por Escherichia coli/tratamento farmacológico , Humanos , Injeções Intravenosas , Intubação Intratraqueal , Infecções por Klebsiella/tratamento farmacológico , Placebos , Infecções por Proteus/tratamento farmacológico , Infecções por Pseudomonas/tratamento farmacológico , Sisomicina/metabolismo , Sisomicina/uso terapêutico , TraqueotomiaRESUMO
To evaluate whether the addition of an aminoglycoside might enhance the clinical efficacy of ceftazidime in cystic fibrosis patients with acute exacerbations of chronic Pseudomonas lung infections we carried out a prospective, comparative, randomized blind study with three schedules: ceftazidime vs. ceftazidime plus sisomicin (C/S) vs. piperacillin plus sisomicin, for a total of 60 courses of 14 days of treatment. Each treatment led to clinical and radiologic improvement with marked reduction of signs of acute infection. Statistically there was no significant difference in clinical responses among the schedules. No side effect appeared during treatments with ceftazidime or C/S. Hyperpyrexia was seen in 35% of patients receiving piperacillin. Decrease in Pseudomonas aeruginosa count to less than 10(5) colony-forming units/ml of sputum was achieved in 60% of patients treated with C/S and in 30% of patients who received ceftazidime or piperacillin plus sisomicin (statistically not significant). A transient increase in mean geometric minimal inhibitory concentrations for ceftazidime and piperacillin was observed at the end of the combined therapies. A larger percentage of persistent resistant strains of P. aeruginosa was seen after the combined therapies. We conclude that ceftazidime as monotherapy may be an effective alternative in Pseudomonas lung infections in cystic fibrosis patients. Its clinical efficacy seems not to be enhanced by the addition of an aminoglycoside, although reduction of Pseudomonas in the sputum was better achieved by the combination of C/S.
Assuntos
Ceftazidima/uso terapêutico , Fibrose Cística/complicações , Pneumonia/tratamento farmacológico , Infecções por Pseudomonas/tratamento farmacológico , Sisomicina/uso terapêutico , Adolescente , Adulto , Análise de Variância , Ceftazidima/administração & dosagem , Criança , Pré-Escolar , Quimioterapia Combinada , Feminino , Humanos , Masculino , Piperacilina/administração & dosagem , Piperacilina/uso terapêutico , Pneumonia/etiologia , Estudos Prospectivos , Pseudomonas/efeitos dos fármacos , Pseudomonas/crescimento & desenvolvimento , Infecções por Pseudomonas/etiologia , Distribuição Aleatória , Sisomicina/administração & dosagem , Escarro/microbiologiaRESUMO
A 27-year-old woman, without compromised immunodefenses, experienced a Listeria meningoencephalitis, with brainstem symptoms. The identified agent exhibited poor susceptibility to usual effective antibiotics, except for penicillins. Knowledge of past history of an allergic reaction to beta-lactam antibiotics lead to appropriate therapy after acute intravenous desensitization of the patient to amoxicillin. Treatment resulted in therapeutic administration rate over 24 h, and in rapid regression of clinical and biological disorders.
Assuntos
Amoxicilina/uso terapêutico , Dessensibilização Imunológica/métodos , Hipersensibilidade a Drogas/etiologia , Listeriose/tratamento farmacológico , Meningoencefalite/tratamento farmacológico , Tianfenicol/uso terapêutico , Adulto , Amoxicilina/administração & dosagem , Amoxicilina/efeitos adversos , Líquido Cefalorraquidiano/citologia , Líquido Cefalorraquidiano/microbiologia , Hipersensibilidade a Drogas/prevenção & controle , Quimioterapia Combinada , Feminino , Humanos , Infusões Intravenosas , Injeções Espinhais , Contagem de Leucócitos , Listeriose/líquido cefalorraquidiano , Listeriose/microbiologia , Meningoencefalite/líquido cefalorraquidiano , Meningoencefalite/microbiologia , Testes de Sensibilidade Microbiana , Sorotipagem , Sisomicina/administração & dosagem , Sisomicina/uso terapêutico , Tianfenicol/administração & dosagem , Falha de TratamentoRESUMO
Sisomicin was administered as a single daily intramuscular injection (160 mg) or as two daily injections (80 mg) to 50 patients with bacteriuria superimposed on chronic urologic diseases in a randomized controlled fashion. The administration of two daily doses was significantly more effective (P less than 0.01) in achieving cure than the injection of a single daily dose. The renal function, as expressed by creatinine clearance, became impaired significantly more often (P less than 0.05) in the patients receiving the single daily dose of sisomicin.
Assuntos
Antibacterianos/administração & dosagem , Bacteriúria/tratamento farmacológico , Sisomicina/administração & dosagem , Adulto , Idoso , Bacteriúria/microbiologia , Ensaios Clínicos como Assunto , Esquema de Medicação , Feminino , Humanos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Sisomicina/metabolismo , Sisomicina/uso terapêutico , Fatores de Tempo , Infecções Urinárias/tratamento farmacológico , Infecções Urinárias/microbiologiaRESUMO
A comparative study was performed using three routes of administration of sisomicin (1 mg/kg as single dose): intramuscular injection, intravenous rapid injection, and 1-hour infusion. Intravenous administration resulted in higher blood levels immediately after the injections than by the intramuscular route; however, later, the intramuscular injection resulted in optimal blood levels. High levels of sisomicin which were bactericidal for most Gram-negative bacilli were found in the urine of the treated patients. The antimicrobial activity of the serum obtained 1 hour after administration of sisomicin, as determined against 20 strains of Gram-negative microorganisms isolated from blood cultures, was identical with all three routes of administration of sisomicin.
Assuntos
Antibacterianos/administração & dosagem , Sisomicina/administração & dosagem , Adulto , Idoso , Bioensaio , Infecções por Enterobacteriaceae/tratamento farmacológico , Feminino , Humanos , Infusões Parenterais , Injeções Intramusculares , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Modelos Biológicos , Infecções por Pseudomonas/tratamento farmacológico , Sisomicina/metabolismo , Sisomicina/uso terapêutico , Fatores de TempoRESUMO
The efficacy and safety of the two aminoglycoside antibiotics, sisomicin and gentamicin, were investigated in a prospective randomized study of 100 elderly male patients with complicated urinary tract infections. Both drugs were administered intramuscularly, sisomicin twice daily and gentamicin three times daily according to body weight. All bacteria isolated from the urine were sensitive to both antibiotics by disk sensitivity method. Seventy per cent of the patients treated with sisomicn and 63 per cent of those treated with gentamicin were cured of infection. There was no apparent toxicity noted from either drug. The twice daily sisomicin administration appeared to be as effective and safe as the three times daily administration of gentamicin in the treatment of complicated urinary tract infections.
Assuntos
Antibacterianos/uso terapêutico , Gentamicinas/uso terapêutico , Sisomicina/uso terapêutico , Infecções Urinárias/tratamento farmacológico , Ensaios Clínicos como Assunto , Avaliação de Medicamentos , Gentamicinas/administração & dosagem , Gentamicinas/efeitos adversos , Humanos , Masculino , Sisomicina/administração & dosagem , Sisomicina/efeitos adversosRESUMO
One hundred and thirty-nine febrile episodes in 120 patients were treated with sisomicin after a combination of carbenicillin and a cephalosporin antibiotic had failed. These patients were randomized to receive sisomicin either by continuous or by intermittent infusion. The response rate for patients treated with sisomicin was 61 percent by continuous infusion and 46 percent by intermittent infusion, which was not statistically significant. Pneumonia, septicemia, and soft tissue infections were the most frequent infections. Most (96 percent) of the identified pathogens were gram-negative bacilli with the most frequent being Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa. The response rate was higher in those patients whose neutrophil count increased or remained the same while on therapy. The worst response was obtained if there was a decrease in the neutrophil count during therapy. The major toxicity of sisomicin was found to be azotemia and occurred in 17 percent of episodes treated by continuous infusion and in 21 percent treated by intermittent infusion. Hearing loss in the high frequency range occurred in five patients. Sisomicin is effective in the treatment of gram negative infections in neutropenic cancer patients.
Assuntos
Gentamicinas/administração & dosagem , Sisomicina/administração & dosagem , Adolescente , Adulto , Idoso , Infecções Bacterianas/complicações , Infecções Bacterianas/tratamento farmacológico , Feminino , Humanos , Infusões Parenterais , Injeções Intravenosas , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Neutropenia/complicações , Sisomicina/efeitos adversos , Sisomicina/uso terapêutico , Uremia/induzido quimicamenteRESUMO
Clinical efficacy of a new aminoglycoside antibiotic, sisomicin, was evaluated in 14 patients with acute chest infections (12 cases with pneumonia and 2 with bronchitis). They were selected taking into account the isolation of sisomicin-sensitive Gram-negative bacilli in a sputum specimen collected prior to therapy. Local predisposing factors were present in 4 patients whereas general predisposing factors were present in 4 patients whereas general predisposing factors were recognizable in 9. Klebsiella was isolated in 5 cases, E. coli in 5 cases, Proteus in 4 cases, P. aeruginosa in 2 cases, Ct-trobacter and Providencia each in one. In all patients the bacteriological finding was negative after the cycle of therapy; clinical outcome was uniformly favourable (11 patients healed, 3 got better). No significant adverse effects due to the antibiotic was noted.